Ana Teijo Quintáns

Ana Teijo Quintáns

Auto-generated profile, based on publicly available information

Ana Teijo Quintáns

Pathology Department, Gastrointestinal and Neuroendocrine Tumors Research Group, Hospital Universitario 12 de Octubre, Research Institute (Imas12), Madrid, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MRMaria Carmen Riesco-Martinez
Maria Carmen Riesco-Martinez
JCJaume Capdevila
Jaume Capdevila
VAVicente Alonso
Vicente Alonso
PJPaula Jimenez-Fonseca
Paula Jimenez-Fonseca
ATAlex Teule
Alex Teule
RGRocio Garcia-Carbonero
Rocio Garcia-Carbonero
The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine neoplasms (NENs) is rather poor. The addition of immune checkpoint inhibition to platinum-based chemotherapy may improve survival. NICE-NEC (NCT03980925) is a single-arm, phase II trial that recruited chemotherapy-naive, unresectable advanced or metastatic G3 NENs of gastroenteropancreatic (GEP) or unknown origin. Patients received nivolumab 360 mg intravenously (iv) on day 1, carboplatin AUC 5 iv on day 1, and etoposide 100 mg/m2/d iv on days 1–3, every 3 weeks for up to six cycles, followed by nivolumab 480 mg every 4 weeks for up to 24 months, disease progression, death or unacceptable toxicity. The primary endpoint was the 12-month overall survival (OS) rate (H0 50%, H1 72%, β 80%, α 5%). Secondary endpoints were objective response rate (ORR), duration of response (DoR), progression-free survival (PFS), and safety. From 2019 to 2021, 37 patients were enrolled. The most common primary sites were the pancreas (37.8%), stomach (16.2%) and colon (10.8%). Twenty-five patients (67.6%) were poorly differentiated carcinomas (NECs) and/or had a Ki67 index >55%. The ORR was 56.8%. Median PFS was 5.7 months (95%CI: 5.1-9) and median OS 13.9 months (95%CI: 8.3-Not reached), with a 12-month OS rate of 54.1% (95%CI: 40.2-72.8) that did not meet the primary endpoint. However, 37.6% of patients were long-term survivors (>2 years). The safety profile was consistent with previous reports. There was one treatment-related death. Nivolumab plus platinum-based chemotherapy was associated with prolonged survival in over one-third of chemonaïve patients with G3 GEP-NENs, with a manageable safety profile.

12 March 2025 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
MAMaría Alsina
María Alsina
AQAna Teijo Quintáns
Ana Teijo Quintáns
Miriam CuatrecasasMiriam Cuatrecasas
Miriam Cuatrecasas
MFMª Jesús Fernández-Aceñero
Mª Jesús Fernández-Aceñero
AMAna Fernández Montes
Ana Fernández Montes
MCMar Iglesias Coma
Mar Iglesias Coma
Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA. Four key biomarkers are essential for targeted therapy: HER2 overexpression/amplification, deficient mismatch repair/microsatellite instability (dMMR/MSI), PD-L1, and Claudin18.2 expression. Immunohistochemistry is the recommended method for these biomarkers evaluation. In addition, the assessment of biomarkers like FGFR2b is likely to become routine in the near future. Experts from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have formed a consensus to optimize biomarker detection and usage in clinical practice. Their recommendations aim to improve personalized treatment strategies for GEA and ESCC patients, integrating new diagnostic insights into routine care.

5 March 2023 in Molecular Oncology
Verified
Journal Article
Open access
BSBeatriz Soldevilla
Beatriz Soldevilla
ALAlberto Lens‐Pardo
Alberto Lens‐Pardo
PEPaula Espinosa‐Olarte
Paula Espinosa‐Olarte
CCCarlos Carretero‐Puche
Carlos Carretero‐Puche
SMSonia Molina‐Pinelo
Sonia Molina‐Pinelo
RGRocio Garcia-Carbonero
Rocio Garcia-Carbonero
Neuroendocrine neoplasms (NENs) are mutationally quiet (low number of mutations/Mb), and epigenetic mechanisms drive their development and progression. We aimed at comprehensively characterising the microRNA (miRNA) profile of NENs, and exploring downstream targets and their epigenetic modulation. In total, 84 cancer‐related miRNAs were analysed in 85 NEN samples from lung and gastroenteropancreatic (GEP) origin, and their prognostic value was evaluated by univariate and multivariate models. Transcriptomics (N = 63) and methylomics (N = 30) were performed to predict miRNA target genes, signalling pathways and regulatory CpG sites. Findings were validated in The Cancer Genome Atlas cohorts and in NEN cell lines. We identified a signature of eight miRNAs that stratified patients in three prognostic groups (5‐year survival of 80%, 66% and 36%). Expression of the eight‐miRNA gene signature correlated with 71 target genes involved in PI3K–Akt and TNFα–NF‐kB signalling. Of these, 28 were associated with survival and validated in silico and in vitro. Finally, we identified five CpG sites involved in the epigenetic regulation of these eight miRNAs. In brief, we identified an 8‐miRNA signature able to predict survival of patients with GEP and lung NENs, and identified genes and regulatory mechanisms driving prognosis in NEN patients.

5 September 2022 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
DADiego Aldave
Diego Aldave
ATAna Teijo
Ana Teijo
CAClaudia Abril
Claudia Abril
LCLaura Cerezo
Laura Cerezo
Tailgut cysts (TGCs) are rare tumours which can undergo malignant transformation. The gold standard of treatment is complete surgical excision. Multidisciplinary assessment is advisable in order to apply adjuvant treatment. Postoperative radiotherapy should be given in case of compromised surgical margins or other factors such as high histological grade or perineural and lymphovascular invasion. Here, we present a case of a squamous cell carcinoma arising from a retrorectal TGC treated with surgery and postoperative radiotherapy and review the main indications and techniques of this therapy.

28 June 2025 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
MAMaría Alsina
María Alsina
AQAna Teijo Quintáns
Ana Teijo Quintáns
Miriam CuatrecasasMiriam Cuatrecasas
Miriam Cuatrecasas
MFMª Jesús Fernández-Aceñero
Mª Jesús Fernández-Aceñero
AMAna Fernández Montes
Ana Fernández Montes
MCMar Iglesias Coma
Mar Iglesias Coma